Source: CMS.gov — Medicare GLP-1 Bridge
If you have been waiting for Medicare to cover GLP-1 medications like Wegovy or Zepbound, that wait is almost over. Starting July 1, 2026, a new federal program called the Medicare GLP-1 Bridge will give eligible Medicare beneficiaries access to certain weight loss drugs for just $50 per month.
This is a significant change. Medicare has historically excluded weight loss medications from coverage. The GLP-1 Bridge is a short-term federal demonstration program that changes that, at least for now.
Here is what you need to know before it launches.
Key Takeaways
- The Medicare GLP-1 Bridge launches July 1, 2026 and runs through December 31, 2027.
- Covered drugs include Wegovy, Foundayo (orforglipron), and Zepbound (KwikPen only), prescribed for weight management only.
- Beneficiaries enrolled in a Part D plan or Medicare Advantage with drug coverage may qualify.
- The flat copay is $50 per month and does not count toward your Part D out-of-pocket spending.
- Your doctor handles the prior authorization. You do not need to enroll separately.
- Ozempic and Mounjaro are not included in this program.
- Program details are subject to change. Confirm current information with CMS or a licensed advisor before making coverage decisions.
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a federal demonstration program running from July 1, 2026 through December 31, 2027 that allows eligible Medicare Part D enrollees to access approved GLP-1 weight loss medications for a flat $50 monthly copay.
The program is run by the Centers for Medicare and Medicaid Services (CMS) and was announced by CMS on December 23, 2025. It is designed to give Medicare Part D enrollees access to approved GLP-1 weight loss medications while a longer-term solution — the BALANCE Model — is developed.
The program operates separately from your regular Part D drug plan. That means your insurance carrier does not need to add these drugs to their formulary for you to access them. CMS is managing the program directly. According to CMS, Humana — the current administrator of the Limited Income Newly Eligible Transition (LI NET) program — is serving as the central processor for prior authorization, claims adjudication, and pharmacy payments.1
Which Drugs Are Covered?
Three GLP-1 medications are currently available through the Bridge program when prescribed specifically for weight management:
| Drug | Covered Under GLP-1 Bridge? | Notes |
|---|---|---|
| Wegovy (semaglutide) | Yes | All formulations, including tablet form |
| Foundayo (orforglipron) | Yes | All formulations; FDA approved April 1, 20262 |
| Zepbound (tirzepatide) | Yes — KwikPen only | Single-dose vials and pens are not covered3 |
| Ozempic (semaglutide) | No | Not included in the Bridge program |
| Mounjaro (tirzepatide) | No | Not included in the Bridge program |
| Rybelsus (semaglutide) | No | Not included in the Bridge program |
If your doctor has prescribed one of the covered drugs for a different condition — such as Wegovy for cardiovascular risk reduction — that would go through your regular Part D plan instead, since the Bridge only covers weight management uses.
Who Qualifies?
The program is available nationwide to Medicare beneficiaries enrolled in a standalone Part D plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD).
To qualify, your doctor will need to submit a prior authorization request. The eligibility criteria below are drawn directly from CMS prior authorization requirements for this program, as published on the CMS GLP-1 Bridge page. You may qualify if you:
- Have a BMI of 35 or higher, or
- Have a BMI of 30 or higher with certain conditions such as uncontrolled high blood pressure, heart failure with preserved ejection fraction, or chronic kidney disease stage 3a or above, or
- Have a BMI of 27 or higher with a history of pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Your doctor attests that you met these criteria when you first started GLP-1 therapy, so even if your BMI has changed since then, you may still be eligible.
What Will It Cost You?
Your out-of-pocket cost is a flat $50 copay per monthly supply, regardless of which phase of your Part D benefit you are in.
There is one important detail to be aware of: that $50 does not count toward your Part D true out-of-pocket (TrOOP) spending. This means it will not help you reach the catastrophic coverage threshold faster.3 If you are not sure how your current plan’s out-of-pocket structure works, our guide on how Medicare Part D works can help clarify.
Low-income subsidy (Extra Help) cost-sharing does not apply to the Bridge program copay either.
How Do You Access the Program?
You do not need to do anything to enroll in the GLP-1 Bridge directly. Here is how it works:
- Talk to your doctor about whether you qualify
- Your doctor submits a prior authorization request to the central processor
- If approved, your doctor writes a prescription for an eligible GLP-1 drug
- You fill the prescription at a participating pharmacy and pay the $50 copay
You do not need to contact your Medicare plan or ask them to add the drug to your coverage.
Not Sure If You Qualify?
A licensed Medicare advisor can review your current plan and help you understand exactly how the GLP-1 Bridge applies to your coverage.
Schedule a Free Consultation
What Happens After 2 027?
The GLP-1 Bridge is a temporary program. CMS is simultaneously developing a longer-term model called the BALANCE Model, which is intended to provide ongoing GLP-1 coverage through Part D. The Bridge program is designed to provide access while that longer-term solution is finalized.
CMS has stated that the Bridge will remain in place through the end of 2027 to allow time for the BALANCE Model to be implemented. How this ultimately affects your coverage will depend in part on the type of plan you are enrolled in, whether that is Original Medicare, a Medicare Advantage plan, or a Medigap policy.
Is This Right for You?
Whether this program makes sense for you depends on your current health situation, the medications you are already taking, and how your plan is set up. A licensed Medicare advisor can review your specific coverage and help you understand exactly what to expect, including how this might interact with your existing Part D benefits.
Program details are subject to change. Always confirm current eligibility and coverage information directly with CMS at cms.gov or with a licensed Medicare advisor before making any coverage decisions.
If you have questions about how the Medicare GLP-1 Bridge applies to your coverage, we are here to help. Schedule a free consultation with a Medicare Information Project advisor today.
Frequently Asked Questions
Does the $50 copay count toward my Medicare deductible or out-of-pocket maximum?
No. The $50 monthly copay under the Medicare GLP-1 Bridge does not count toward your Part D true out-of-pocket (TrOOP) spending and does not apply to your deductible. This is because the program operates outside the standard Part D benefit payment flow.
Can I use the GLP-1 Bridge if I have a Medicare Supplement (Medigap) plan?
Yes, as long as you are also enrolled in a standalone Part D plan (PDP) alongside your Medigap policy. Medigap alone does not include prescription drug coverage, so Part D enrollment is required to participate. If you have questions about how your Medigap plan interacts with Part D, a licensed advisor can walk you through it.
Can I use the GLP-1 Bridge if I have Medicare Advantage?
Yes, if your Medicare Advantage plan includes prescription drug coverage (MA-PD). Beneficiaries in HMO, HMO-POS, and local or regional PPO plans with drug coverage are eligible. However, beneficiaries in private fee-for-service plans and certain other plan types are not eligible unless also enrolled in a standalone PDP.
Does Extra Help (Low-Income Subsidy) reduce my $50 copay?
No. Low-income cost-sharing subsidies do not apply to the Bridge program copay. All eligible beneficiaries pay the same flat $50 per monthly supply regardless of income.
What if my doctor prescribes Zepbound for sleep apnea instead of weight loss?
That prescription would go through your regular Part D plan, not the GLP-1 Bridge. The Bridge only covers eligible GLP-1 drugs when prescribed specifically for weight management. If your drug is coverable under the basic Part D benefit for another approved use, your plan’s normal formulary and exception processes apply.
Is this program available in Florida?
Yes. The Medicare GLP-1 Bridge is a nationwide program available in all states and territories, including Florida.
How long will the GLP-1 Bridge last?
The program is currently authorized through December 31, 2027. CMS extended it through that date while work continues on the longer-term BALANCE Model. Program details remain subject to change, so check cms.gov or speak with a licensed advisor for the most current information.
Get the expert support that you need!
1 Source: CMS.gov — Medicare GLP-1 Bridge FAQ, last modified May 6, 2026. CMS states: “CMS will be utilizing Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Medicare GLP-1 Bridge.”
2 Source: FDA Approval Letter — Foundayo (orforglipron), NDA 220934, U.S. Food and Drug Administration, April 1, 2026.
3 Source: CMS.gov — Medicare GLP-1 Bridge FAQ, last modified May 6, 2026. On Zepbound formulations: “The single-dose vial and single-dose pen formulations of Zepbound will not be available through the Medicare GLP-1 Bridge.” On TrOOP: “no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan.”